The anti-inflammatory potential of nicotinamide (vitamin B3) in Juvenile Idiopathic Arthritis (JIA): modulating Treg numbers and function with nicotinamide
Authors' conclusion
Given its established safety in both adults and children, NAM represents a promising future candidate for adjunctive therapy in JIA by restoring the balance between regulatory and effector T cells.
Study context
- Population
- JIA patients (PBMCs and SFMCs) and healthy controls (PBMCs); pilot: JIA patients receiving oral nicotinamide (NAM)pilot: 6 JIA patients
- Comparison
- NAM treatment vs untreated cells in vitro; oral NAM 1.8 g/m² daily for 3 days (pilot)
Methodological detailsin vitro, exploratory pilot phase II clinical study, Pilot: NAM measured in paired blood plasma and SF after oral 1.8 g/m² daily for 3 days
- In vitro
- Exploratory pilot phase II clinical study
- Pilot: NAM measured in paired blood plasma and SF after oral 1.8 g/m² daily for 3 days
Main finding
As reported in the abstract
- NAM significantly increased the proportion of FOXP3-expressing CD4+ T cells in both PBMCs and SFMCs
- NAM significantly increased Treg suppressive capacity in PBMCs from healthy controls in vitro
- Comparable NAM concentrations in plasma and SF after oral administration (pilot, 6 JIA patients)
Original publication
The anti-inflammatory potential of nicotinamide (vitamin B3) in JIA: modulating Treg numbers and function with nicotinamide. Arthritis Res Ther. Published 18 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →